Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.46) EPS for the quarter, hitting the consensus estimate of ($0.46), Zacks reports.
Prelude Therapeutics Stock Down 16.8 %
Shares of Prelude Therapeutics stock traded down $1.04 during trading on Wednesday, hitting $5.16. 191,164 shares of the stock were exchanged, compared to its average volume of 80,382. The stock’s fifty day moving average is $4.61 and its 200 day moving average is $4.27. Prelude Therapeutics has a 12 month low of $1.66 and a 12 month high of $6.80.
Analysts Set New Price Targets
Separately, Barclays lowered shares of Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 target price for the company. in a research note on Thursday, June 20th.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
Featured Stories
- Five stocks we like better than Prelude Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Brinker International’s Price Dip is an Appetizing Entry Point
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Stocks That Could Beat the September Blues
- 3 Warren Buffett Stocks to Buy Now
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.